UK Companies House feature
BRISTOL LABORATORIES LIMITED
Cash
£516K
+14.7% vs 2023
Net assets
£29M
+5% vs 2023
Employees
531
+11.3% vs 2023
Profit before tax
£900K
-83.6% vs 2023
Profile
- Company number
- 03393503
- Status
- Active
- Incorporation
- 1997-06-27
- Last accounts made up
- 2024-03-31
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Net assets
5-year trend · vs UK Healthcare median
Accounts
5-year trend · latest 2024-03-31
| Metric | Trend | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 |
|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | |
| Operating profit | — | — | — | — | — | |
| Profit before tax | — | — | — | £5,478,027 | £900,205 | |
| Net profit | — | — | — | £5,970,621 | £860,542 | |
| Cash | — | — | — | £450,003 | £515,934 | |
| Total assets less current liabilities | — | — | — | £30,836,602 | £30,840,948 | |
| Net assets | — | — | — | £27,697,738 | £29,071,355 | |
| Equity | — | — | — | £27,697,738 | £29,071,355 | |
| Average employees | — | — | — | 477 | 531 | |
| Wages | — | — | — | £16,476,771 | £17,759,879 |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- King & King Chartered Accountants & Statutory Auditors
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors are of the opinion that the company has adequate resources to continue in operational existence for the foreseeable future on the understanding that the company has the on-going support from its bankers who are providing facilities to the company and sales financing to manage liquidity. Thus, the directors have adopted the going concern basis of accounting in preparing the financial statements.”
Subsidiaries
- Brilpharma Private Limited · 100% held · India
- Brilpharma S.L. · 70% held · Spain
Significant events
- “On 10 June 2024, Bristol Laboratories Ltd partially divested its investment in Brillpharma S.L. by disposing of a 29% equity stake for £6.7m, reducing its controlling interest from 70% to 49%, which would result in a reclassification from a subsidiary to an associate.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 7 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| NAIR KODUPURATH, Sreekumar, Mr. | Secretary | 2014-04-02 | — | — |
| RAMACHANDRAN, Priti | Director | 2016-11-01 | May 1982 | British |
| RAMACHANDRAN, Thembalath | Director | 2008-11-01 | Nov 1949 | British |
Show 7 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| NAIR KODUPURATH, Sreekumar | Secretary | 2006-04-27 | 2014-04-02 |
| FIRST SECRETARIES LIMITED | Corporate Nominee Secretary | 1997-06-27 | 2006-06-07 |
| KODUPURATH, Sreekumar Nair, Mr. | Director | 2014-04-02 | 2014-04-02 |
| NAIR KODUPURATH, Sreekumar | Director | 2006-04-27 | 2014-04-02 |
| PASHINE, Sanjay Shrikishan | Director | 2017-01-09 | 2021-12-31 |
| PUTHENVILAYIL MATHAIKUTTY, Raju | Director | 1997-06-27 | 2021-02-14 |
| FIRST DIRECTORS LIMITED | Corporate Nominee Director | 1997-06-27 | 1997-06-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Bristol Laboratories Group Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 146 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-04-07 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2026-03-19 | CH01 | officers | change person director company with change date |
| 2026-01-15 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-03-17 | AA | accounts | accounts with accounts type full |
| 2025-02-24 | MR04 | mortgage | mortgage satisfy charge full |
| 2025-02-24 | MR04 | mortgage | mortgage satisfy charge full |
| 2025-02-19 | MR04 | mortgage | mortgage satisfy charge full |
| 2025-02-19 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2024-10-31 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-10-14 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2024-06-24 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2024-06-24 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2023-12-15 | MR05 | mortgage | mortgage charge part both with charge number |
| 2023-10-18 | CS01 | confirmation-statement | confirmation statement with updates |
| 2023-07-25 | AA | accounts | accounts with accounts type full |
| 2023-07-25 | AA | accounts | accounts with accounts type full |
| 2023-05-04 | CS01 | confirmation-statement | confirmation statement with updates |
| 2023-05-04 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2022-06-06 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2022-05-26 | MR04 | mortgage | mortgage satisfy charge full |
Credit score
Altman Z″ (private-firm) · reference 2024-03-31
1.47
GREY ZONE
Altman Z″
- Working capital / Total assets 0.071 × 6.56 = +0.46
- Retained earnings / Total assets 0.000 × 3.26 = +0.00
- EBIT / Total assets 0.028 × 6.72 = +0.19
- Book equity / Total liabilities 0.783 × 1.05 = +0.82
Bands: > 2.6 safe · 1.1–2.6 grey · < 1.1 distress. Z″ is a public-formula baseline, not a substitute for adverse-data signals (CCJs, charges, gazette notices) — those land in a later pass.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory